EBS halted on Nov 3 2026 at $6.46

THE SESSION

• 09:30 ETOpened at $5.51, -14.4% on the previous close of $6.44
• 09:30 ETRegular-session low, $5.51
• 09:32 ETHalted (M); resumed 09:37 ET, after 5 minutes
• 10:35 ETRegular-session high, $7.22
• 15:59 ETLast trade of the regular session, $6.25, -3.0% on the previous close of $6.44
• Volume: 2.8M shares in regular hours, 63K before the open

EBS opened at $5.51, down from the previous close, then halted at 09:32 ET after rising to $6.46 by TapeRank’s 09:33 ET record; it resumed five minutes later and reached a $7.22 high at 10:35 ET before ending the regular session at $6.25. The stock traded 2.8M shares during regular hours, but TapeRank found no committed filing or news explanation for the move. The latest items included a 10-Q, third-quarter earnings materials, and guidance lowered from $645M–$675M to $600M–$645M, alongside reported quarterly sales below estimates.

WRITTEN TUE NOV 3 2026 16:00 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE

FILINGS AND NEWS · 24H BEFORE THE MOVE

• MON 17:39 ET10-Q — 10-Q 9.30.26SEC 10-Q
• MON 17:35 ETEmergent BioSolutions Q3 2026 Earnings Call TranscriptBenzinga
• MON 16:32 ETEmergent BioSolutions Lowers FY2026 Sales Guidance from $645.000M-$675.000M to $600.000M-$645.000M vs $657.133M EstBenzinga
• MON 16:08 ETEmergent BioSolutions Q3 Adj. EPS $(0.36) Beats $(0.39) Estimate, Sales $110.000M Miss $123.200M EstimateBenzinga
• MON 16:06 ET8-K — Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and ExhibitsSEC 8-K